Antibodies to histones (AHA) are commonly found in patients with systemic lupus erythematosus (SLE). However, the full profile of AHA and their clinical associations remains unclear. A total of 111 patients with SLE were studied, including 13 patients in whom multiple serum samples were available over several years. IgM, IgG, and IgA antibodies to total core histones, histone complexes, and individual histones were determined by highy sensitive enzyme linked immunosorbent assays (ELISAs). Antibodies to histones were detected in 74% of serum samples, though only at low levels in half of these. Antibodies to each of the individual histones (HI, H2A, H2B, H3, H4) occurred with similar frequencies except for IgG and IgA antibodies to H4, which were uncommon. In contrast, antibodies to the histone complexes H2A-H2B and H3-H4 were detected in only two serum samples and thus do not appear to be a feature of SLE. All three major isotypes of AHA were common and usually occurred with similar frequencies to one another for the various histone specificities.
Antibodies to histones (AHA) are among the more common autoantibodies seen in patients with systemic lupus erythematosus (SLE). In addition, the known structures of the histones1 2 and the use of solid phase assays have allowed their nature to be defined in greater detail than most other autoantibodies. Nonetheless, many reports have conflicting findings: the prevalence of AHA in patients with SLE has been variously reported to be as low as 21%3 or up to 81%.4 5 Some workers have observed associations between AHA and indices of disease activity'9 whereas others have failed to show this. 1'12 The specificity of AHA for individual histone components has also differed from study to study.3 5 6 10 13-20 In this work, we determined all the major isotypes of AHA (including antibodies to individual histones and histone complexes) in a large cohort of patients with SLE in both cross sectional and longitudinal studies. This has allowed the definition of the prevalence and clinical associations of AHA in our patients with SLE as well as addressing some of the factors that may have given rise to the disparities between earlier reports.
Patients and methods

PATIENTS AND SERUM SAMPLES
One hundred and eleven patients with SLE with serum samples stored at the department of rheumatology, Royal North Shore Hospital from 1970 to 1986 formed the basis of this study. All patients fulfilled the American Rheumatism Association revised criteria for SLE.2' All serum samples had been stored in aliquots at -20°C.
Patients charts were reviewed for clinical and laboratory findings including mucocutaneous lesions, arthritis, serositis, renal involvement, neurological lesions, haematological tests, antinuclear antibodies, rheumatoid factor, antibodies to native DNA, complement concentrations, and antibodies to extractable nuclear antigens.
In Antibodies to histone were measured by an enzyme linked immunosorbent assay (ELISA) as described previously.25 26 Briefly, a preparation that was found to contain core histones (H2A, H2B, H3, H4) and a preparation containing HI were obtained from Sigma Chemical. Individual histones were purified by the method of Bohm et al.27 Histone complexes were prepared as previously described.25 28 ELISA plates were coated with histones diluted in phosphate buffered saline (PBS), pH 7-3 and then coated with PBS containing Tween 20 (PBST). Samples were diluted in PBST and bound antibody detected with enzyme conjugated antibodies to human IgM, IgG, or IgA (Silenus). Enzyme substrate was added and the colour change monitored with an automated spectrophotometer. Preliminary experiments determined that none of 30 AHA positive serum samples bound to PBST coated plates in the absence of antigen.
All serum samples were tested for antibodies to total core histones (AcHA) and HI. The upper limit of the normal level in all assays was defined as the mean plus three standard deviations of the absorbance of six serum samples from healthy blood donors, which were representative of 80 serum samples used to determine the normal range. These six serum samples and the one positive control were run in all assays. Units for AcHA were determined by ascribing unit values to the positive control serum sample (100 U for all isotypes) and to the upper limit of the normal level (12, 30 , and 30 for IgG, IgM and IgA, respectively). Only serum samples The prevalences of other features recorded in these patients were: Raynaud's phenomenon (68%), vasculitis (26%), antibodies to extractable nuclear antigen (52%), decreased complement C3 (41%) and C4 (74%), and rheumatoid factor (18%).
In the same serum samples used for the estimation of AHA, raised levels of antibodies to native DNA were observed in 32%, decreased complement C3 in 19%, and C4 in 15% of patients.
ANTIBODIES TO HISTONES
Increased levels of AcHA or antibodies to HI of one or more isotypes were found in 74% of the 111 serum samples. Although AcHA were seen in 68% of serum samples, only 32% had AcHA of any isotype raised to greater than twice the normal level. Figure 1 illustrates the range of values of AcHA in the 111 serum samples. Table 2 gives the prevalence of each isotype of AcHA and antibodies to H1. Most serum 
Discussion
The reported prevalence of AHA in unselected patients with SLE has varied from 213 to 81%.4 5 We detected AHA in 74% (AcHA in 68% and antibodies to HI in 55%) of patients, but only 32% of the serum samples with AcHA had greater than twice the normal levels. These results are remarkably similar to the findings of Muller et al,30 who detected AHA in 78% of patients but noted that only 34% had high titres. Consequently, the ability to detect low levels of antibody may explain some of the wide variations in pievalence data. In addition, differences between patient groups, as illustrated in table 1, may go part of the way to explaining disparities in the prevalence and specificities of AHA cited in various reports.
Antibodies to core total histones of the three major isotypes were common and occurred with similar frequencies. Most patients had more than one isotype of AHA which, in longitudinal studies, could persist over many years.
Although it was not possible to study serum samples from patients before the onset of SLE, in no patient was there evidence that a switch from IgM to IgG AHA, with subsequent loss of IgM AHA, had occurred. IgA AHA have been described previously, but not detailed, in patients with SLE.3' From this study, it can be seen that IgA AHA occur at a similar frequency to the other isotypes of AHA.
Several studies have reported the prevalence of antibodies to individual core histones but there has been no general agreement as to the prevalence of each fraction.3 5 6 10 13-20 30 Of the core histones, most have found that antibodies to H2B are common and that antibodies to H4 are uncommon, whereas the reported prevalences of antibodies to H2A and H3 have varied greatly. Antibodies to HI have been reported to be the most common of the antibodies to individual histones in most studies, but this has not been a universal finding. Although several reports have noted a predominance of antibodies to HI and H2B, most agree that a considerable diversity in the profiles of AHA may be seen in patients with SLE. Apart from a single study finding IgA antibodies to HI in 18% of patients with SLE,32 IgA antibodies to individual histones have not been detailed. The data presented here suggest that antibodies to each of the histones, except H4, are common. Furthermore, for the core histones, all three major isotypes occur with similar frequencies, whereas IgM antibodies to HI were less common than the other isotypes of antibodies to HI.
Antibodies to H2A-H2B complexes are characteristic of procainamide related lupus erythematosus33 and have been noted in a minority of patients with idiopathic SLE.17 33 The data presented here confirm that this specificity is uncommon in patients with SLE (less than 2% of patients). Antibodies to H3-H4 complexes were detected in only two patients. This specificity has not been observed previously in patients with SLE, possibly because of its rarity. Nonetheless, a monoclonal antibody to this complex has been described34 and we have found that these antibodies occur in quinidine related lupus erythematosus25 and Felty's syndrome. 26 Very few clinical or laboratory associations were evident, which is consistent with other studies. 35 
